Founded in 2020, Kimialys has created and commercializes an innovative chemistry-based platform that functionalizes surfaces such as nanoparticles, biopuces and electrodes for in-vitro diagnostic and analytical applications. By improving surface treatment, the company aims to boost the sensitivity and reliability of diagnostic tests. The newly raised capital will enable Kimialys to finalize the industrialization of its processes and scale up production capacity. It also plans to launch an initial catalog of ready-to-use kits, broadening its product offering. A portion of the funds will be directed toward intensifying international commercial efforts. Although specific revenue or user metrics are not disclosed, the Series A round indicates investor confidence in the company’s commercialization and growth trajectory.

Total raised

$4M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2025